All 1 tracked stories fall under one category: market-trends. MannKind is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. They are less corroborated than the beat average, carrying 2 original sources each against 4.7 for the same window.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about Trulieve Cannabis
All 1 tracked stories fall under one category: market-trends. MannKind is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. They are less corroborated than the beat average, carrying 2 original sources each against 4.7 for the same window. At 5, the average consequence score sits below the same-window beat average of 5.6. Trulieve Cannabis appears in 1 tracked Healthcare story from February 26, 2026.
Stories tracked
1
Sources per story
2
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 41 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering Trulieve Cannabis. Shared-story counts are live from our verified record — not editorial picks.
Trulieve Cannabis and MannKind reported mixed fourth-quarter results, with Trulieve beating earnings expectations despite a revenue miss. Meanwhile, MannKind delivered a significant revenue beat alongside an earnings shortfall, highlighting the divergent growth trajectories in the cannabis and biopharmaceutical sectors.